Mallinckrodt to Post Q2 2018 Earnings of $1.48 Per Share, Jefferies Group Forecasts (MNK)

Mallinckrodt (NYSE:MNK) – Equities research analysts at Jefferies Group issued their Q2 2018 earnings per share estimates for shares of Mallinckrodt in a note issued to investors on Wednesday, May 9th. Jefferies Group analyst A. Petrone expects that the company will post earnings of $1.48 per share for the quarter. Jefferies Group also issued estimates for Mallinckrodt’s Q3 2018 earnings at $1.75 EPS, Q4 2018 earnings at $1.71 EPS, FY2018 earnings at $6.25 EPS, FY2019 earnings at $6.55 EPS and FY2020 earnings at $7.30 EPS.

Mallinckrodt (NYSE:MNK) last released its earnings results on Tuesday, May 8th. The company reported $1.31 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.23. The firm had revenue of $572.60 million for the quarter, compared to the consensus estimate of $568.78 million. Mallinckrodt had a return on equity of 11.59% and a net margin of 57.56%. The company’s revenue for the quarter was up 2.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.04 EPS.

MNK has been the topic of several other research reports. Leerink Swann cut their target price on Mallinckrodt and set a “market perform” rating on the stock in a research report on Monday, April 23rd. ValuEngine downgraded Mallinckrodt from a “hold” rating to a “sell” rating in a research report on Monday, April 2nd. Wells Fargo reissued a “hold” rating on shares of Mallinckrodt in a research report on Thursday, April 12th. SunTrust Banks started coverage on Mallinckrodt in a research report on Wednesday, April 11th. They set a “hold” rating and a $15.00 target price on the stock. Finally, Oppenheimer reissued a “hold” rating on shares of Mallinckrodt in a research report on Tuesday, February 27th. Three research analysts have rated the stock with a sell rating, fourteen have given a hold rating and five have issued a buy rating to the stock. Mallinckrodt currently has an average rating of “Hold” and a consensus price target of $31.26.

NYSE MNK opened at $15.63 on Monday. The company has a market cap of $1.24 billion, a PE ratio of 2.09, a P/E/G ratio of 0.37 and a beta of 1.13. The company has a debt-to-equity ratio of 1.00, a quick ratio of 1.90 and a current ratio of 2.10. Mallinckrodt has a fifty-two week low of $15.58 and a fifty-two week high of $16.04.

Hedge funds have recently modified their holdings of the business. LMR Partners LLP purchased a new stake in shares of Mallinckrodt in the 4th quarter worth $2,630,000. Fox Run Management L.L.C. purchased a new stake in shares of Mallinckrodt in the 4th quarter worth $1,064,000. Virtu Financial LLC lifted its holdings in shares of Mallinckrodt by 78.2% in the 4th quarter. Virtu Financial LLC now owns 16,308 shares of the company’s stock worth $368,000 after buying an additional 7,159 shares during the period. California Public Employees Retirement System lifted its holdings in shares of Mallinckrodt by 25.9% in the 4th quarter. California Public Employees Retirement System now owns 332,306 shares of the company’s stock worth $7,497,000 after buying an additional 68,336 shares during the period. Finally, K2 Principal Fund L.P. lifted its holdings in shares of Mallinckrodt by 143.7% in the 4th quarter. K2 Principal Fund L.P. now owns 113,600 shares of the company’s stock worth $2,563,000 after buying an additional 373,600 shares during the period.

In related news, insider James E. Flynn sold 312,928 shares of the business’s stock in a transaction on Wednesday, May 9th. The stock was sold at an average price of $13.39, for a total transaction of $4,190,105.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.80% of the stock is owned by insiders.

Mallinckrodt Company Profile

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.

Earnings History and Estimates for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply